89Bio's NASH drug meets main goals of mid-stage study

Health

89Bio’s NASH drug meets main goals of mid-stage study

Wed, Mar 22, 2023 0 Comments

(Corrects Refinitiv instrument code in paragraph 1)

(Reuters) -Drug developer 89Bio Inc <ETNB.O> said on Wednesday its drug to treat liver disease non-alcoholic steatohepatitis (NASH) met the main goals of a mid-stage trial.

The company’s shares rose nearly 40% in premarket trading.

(Reporting by Pratik Jain in Bengaluru; Editing by Sriraj Kalluvila)

Previous US FDA declines to approve AbbVie’s Parkinson’s disease therapy

Next Drug developer 89Bio soars as NASH drug succeeds in mid-stage study

Salem News Channel | Today

More Health Headlines

Other News to Consider

Follow SRNNews.com

on Facebook

@SRNNews

Subscribe to our Newsletters RSS Feeds

Editorial Cartoons

Michael Ramirez
Wed, May 31, 2023

X CLOSE

Email to a Friend

89Bio’s NASH drug meets main goals of mid-stage study

(Corrects Refinitiv instrument code in paragraph 1) (Reuters) -Drug developer 89Bio Inc <ETNB.O> said on Wednesday its drug to treat liver disease non-alcoholic steatohepatitis (NASH) met the main goals of a mid-stage trial. The company’s shares rose nearly 40% in premarket trading. (Reporting by Pratik Jain in Bengaluru; Editing by Sriraj Kalluvila)

X close